BofA analyst Derik de Bruin lowered the firm’s price target on NeoGenomics (NEO) to $16 from $19 and keeps a Neutral rating on the shares. Soft Q4 sales led to a 14% stock pullback, though management is confident this miss is only temporary, particularly given the impact of a softer Pharma budget flush, says BofA, which tweaks estimates after the report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Achieves Double-Digit Revenue Growth in 2024
- NeoGenomics Q4 Earnings Call Highlights Growth Amid Challenges
- NeoGenomics: Overcoming Short-term Setbacks with Strategic Growth Initiatives and Leadership Transition
- Buy Rating Maintained for NeoGenomics Despite Mixed Results and Leadership Changes
- Delta flight crashes in Toronto, Southwest cuts corporate roles: Morning Buzz